In this study, s‐p53‐Abs and s‐NY‐ESO‐1‐Abs were evaluated on the same cohort for clinicopathological and prognostic impact in ESCC, gastric cancer, and HCC. This evidence concerns the gene TP53 and hepatocellular carcinoma.